IL1A and acute myeloid leukemia: Finally, the p38 MAPK inhibitor ralimetinib, which had preclinical activity in reducing the proliferative effects of IL-1 in AML, is in clinical trials for ovarian cancer, but has not been tested clinically for hematologic malignancies (95).